Asset Planning Inc Purchases New Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Asset Planning Inc bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 378 shares of the medical research company’s stock, valued at approximately $196,000.

A number of other institutional investors also recently bought and sold shares of TMO. Legacy Investment Solutions LLC purchased a new stake in Thermo Fisher Scientific during the third quarter worth $26,000. Peterson Financial Group Inc. purchased a new stake in Thermo Fisher Scientific during the third quarter worth $27,000. Barrett & Company Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth $28,000. Missouri Trust & Investment Co purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth $29,000. Finally, Endeavor Private Wealth Inc. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $30,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on TMO. Wells Fargo & Company upped their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Morgan Stanley upped their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Evercore ISI dropped their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Scotiabank upped their target price on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research note on Monday, February 3rd. Finally, Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $658.00.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,125 shares of company stock worth $11,231,699 in the last three months. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 1.0 %

Shares of Thermo Fisher Scientific stock opened at $532.63 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The business’s 50 day simple moving average is $548.21 and its 200-day simple moving average is $571.28. The stock has a market capitalization of $203.73 billion, a price-to-earnings ratio of 32.22, a PEG ratio of 3.18 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has authorized a stock repurchase program on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.